COMP <GO>
BVS vs PRCT // FREE CASH FLOW YIELD
Bioventus Inc. (Class A) (NASDAQ) VS. PROCEPT BioRobotics Corporation (NASDAQ) • 15-METRIC TALLY: BVS 7
— PRCT 3
▲ FREE CASH FLOW YIELD LEADER: BVS
LAST: $13.15 (-1.31%) • MKT CAP: $1.12B
fcf-yield
5.77%
LAST: $19.44 (+1.25%) • MKT CAP: $1.10B
fcf-yield
-5.02%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BVS VS. PRCT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BVS | PRCT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 68.30% | 63.70% | +4.60 | BVS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.40% | -35.00% | +45.40 | BVS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.3x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 5.77% | -5.02% | +10.79 | BVS | /fcf-yield <GO> |
| Operating Margin | 9.50% | -33.70% | +43.20 | BVS | /operating-margins <GO> |
| Net Profit Margin | 4.00% | 0.00% | +4.00 | BVS | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 37.20% | -38.10 | PRCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.25 | 3.98 | -1.73 | PRCT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 4/9 | +3.00 | BVS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 50.1 | -4.40 | PRCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 51.2x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.12B | $1.10B | $20.9M | BVS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BVS REV | PRCT REV | BVS GROSS % | PRCT GROSS % | BVS FCF | PRCT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $568.1M | $308.1M | 68.3% | 63.7% | $72.1M | -$58.3M |
| FY 2024 | $573.3M | $224.5M | 67.7% | 61.1% | $37.8M | -$103.6M |
| FY 2023 | $512.3M | $136.2M | — | — | $15.3M | -$108.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BVS // BETA —
PRCT // BETA —